Open AccessAntioxidant and Cardioprotective Evaluation of Some N-(3-Chloro-2-oxo-4- arylazetidin-1-yl)-2-[(4-oxo-2-aryl-4H-chromen-7-yl)oxy]acetamide Derivatives
Author(s) -
Durbhaka S. Padmini,
D. Swarnalatha,
Senthamizh Prasad
Publication year - 2021
Publication title -
asian journal of chemistry/asian journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.145
H-Index - 34
eISSN - 0975-427X
pISSN - 0970-7077
DOI - 10.14233/ajchem.2022.23437
Subject(s) - chemistry , acetamide , antioxidant , dpph , superoxide dismutase , catalase , docking (animal) , cardiotoxicity , baicalein , pharmacology , stereochemistry , biochemistry , organic chemistry , toxicity , medicine , nursing
A series of N-(3-chloro-2-oxo-4-arylazetidin-1-yl)-2-[(4-oxo-2-aryl-4H-chromen-7-yl)oxy]acetamidederivatives [SLP VI 1(a-d)-2(a-d)] were synthesized from 7-hydroxy flavone derivatives through theintermediate Schiff bases. The synthesized compounds were investigated for in vitro antioxidant propertyby DPPH radical scavenging assay. The title compounds with good antioxidant potency were furtherevaluated for possible cardioprotective effect by doxorubicin induced cardiotoxicity. All biochemicalchanges were normalized after oral administration of the test compounds at the dose of 50 μg/kg. Theresults showed the significant (p < 0.05) increase in antioxidant enzymes catalase and superoxidedismutase in heart tissue homogenates. These observations enable us to conclude that the synthesizedderivatives SLP VI 1b, VI 1c, VI 2b and VI 2d have cardioprotective activity against doxorubicininduced cardiotoxicity. Further, an attempt has been made to perform in silico studies on the synthesizedcompounds to predict the interaction between test ligands and prospective cardiovascular protein targetsusing molecular docking tools. The title compounds have good binding affinity with MAPkinase P38and PKCβ cardiovascular targets.